{
    "symbol": "CPIX",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-12 20:53:26",
    "content": " With the addition of Sancuso sales, our product portfolio delivered combined revenues of $11.4 million during the third quarter, a 41% increase over the prior year period. Adjusted earnings for the third quarter were $1.4 million or $0.10 a share, while year-to-date cash flow from operations was $5.6 million, a 28% increase over the same period last year. As a result of the Sancuso acquisition, our total assets grew to $91 million by the end of the third quarter, including $19.5 million in cash. For the 3 months ended September 30, 2022, net revenues from continuing operations were $11.4 million, a 41% increase over the $8.1 million in revenue recorded during the prior year period. Net revenues by product for the third quarter of 2022 included $4 million for Sancuso, $3.9 million for Kristalose, $1.9 million for Vibativ and $0.9 million for Caldolor. Year-to-date, product revenues totaled $11.4 million for Kristalose, $10.8 million for Sancuso, $6 million for Vibativ and $3.1 million for Caldolor. The net loss for the quarter was $408,000, and year-to-date, we have a net loss of $3.1 million when noncash expenses are added back, the resulting adjusted earnings for the third quarter were $1.4 million, a significant improvement of the adjusted loss of $327,000 last year."
}